Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00659984 · ClinicalTrials.gov registry record · Phase 2
N2007-01: Ultratrace™ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk Neuroblastoma
A Phase 2 study, sponsored by Molecular Insight Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT00659984 is a Phase 2 study that has completed, run by Molecular Insight Pharmaceuticals. The registered enrollment target is 15 participants.
The verdict
NCT00659984, a Phase 2 study, has completed, sponsored by Molecular Insight Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
RATIONALE: Radioactive drugs, such as iodine I 131 metaiodobenzylguanidine (MIBG), may carry radiation directly to tumor cells and not harm normal cells. A bone marrow or peripheral stem cell transplant using stem cells from the patient may be able to replace blood-forming cells that were destroyed by I 131 MIBG. PURPOSE: This phase II trial is studying the side effects and best dose of iodine I 131 MIBG followed by a stem cell transplant in treating young patients with relapsed or refractory high-risk neuroblastoma.
Interventions
- DRUG UltratraceTM Iobenguane I 131 Imaging
- DRUG UltratraceTM Iobenguane I 131 Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2008-06 |
| Est. Completion | 2010-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00659984
The ClinicalTrials.gov registry entry for NCT00659984 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Molecular Insight Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which UltratraceTM Iobenguane I 131 Imaging is the first listed.
NCT00659984 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00659984 about?
NCT00659984 is a clinical study titled "N2007-01: Ultratrace™ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk Neuroblastoma". RATIONALE: Radioactive drugs, such as iodine I 131 metaiodobenzylguanidine (MIBG), may carry radiation directly to tumor cells and not harm normal cells. A bone marrow or peripheral stem cell transplant using stem cells from the patient may be able to replace blood-forming cells that were destroyed ...
What is the current status of trial NCT00659984?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2008-06. Estimated completion is 2010-11.
What interventions are being tested in trial NCT00659984?
The interventions under investigation include: UltratraceTM Iobenguane I 131 Imaging (DRUG), UltratraceTM Iobenguane I 131 Therapy (DRUG).
Who is sponsoring clinical trial NCT00659984?
This trial is sponsored by Molecular Insight Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.